---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055716"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T11:12:40.389531+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences Q3 net loss $6.7M; ORCA-2 topline data expected H1 2022

## Summary
- Cash equivalents $33.4M; total operating expenses $6.7M for Q3, $26.0M for 9 months.
- ORCA-2 Phase 3 completed treatment; topline data expected first half 2022.
- ORCA-3 Phase 3 enrollment of ~750 subjects to start by early 2022.
- FDA accepted IND for cytisinicline e-cigarette cessation trial; ORCA-V1 to start Q2 2022.
- Two U.S. patents issued for 3.0 mg TID dosing regimen, expiring 2040.

## SEC filing metadata
- accession: 0001564590-21-055716
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000156459021055716/0001564590-21-055716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000156459021055716/achv-8k_20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055716
- JSON: https://secwatch.observer/filing/0001564590-21-055716.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.